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Objectives: Although many advantages of mitral valve reconstruction have been
demonstrated, whether specific subgroups of patients exist in whom mechan-
ical valve replacement offers advantages over mitral reconstruction remains
undetermined. Methods: This study examined the late results of mitral valve
surgery in patients with mitral insufficiency who received either a St. Jude
Medical valve (n 5 514) or a mitral valve reconstruction with ring annulo-
plasty (n 5 725) between 1980 and 1996. Results: Overall operative mortality
was 7.2% in the patients receiving a St. Jude Medical mitral valve and 5.4% in
those undergoing mitral valve reconstruction (no significant difference); iso-
lated mortality was 2.5% in the St. Jude Medical group and 2.2% in the valve
reconstruction group (no significant difference). The follow-up interval was
more than 5 years for 340 patients with a mean of 39.8 months (98.5%
complete). Overall 8-year freedom from late cardiac death, reoperation, and all
valve-related complications was 72.8% for the St. Jude Medical group and
64.8% for valve reconstruction group (no significant difference). For patients
with isolated, nonrheumatic mitral valve disease, 8-year freedom from late
cardiac death and reoperation was better in the mitral valve reconstruction
group (88.3%) than in the St. Jude Medical valve group (86.0%; p 5 0.05).
Furthermore, Cox proportional hazards regression revealed that mitral valve
reconstruction was independently associated with a lesser incidence of late
cardiac death (p 5 0.04), irrespective of preoperative New York Heart
Association class. However, the St. Jude Medical valve offered better 8-year
freedom from late cardiac death, reoperation, and all valve-related complica-
tions than did mitral valve reconstruction in patients with multiple valve
disease (77.0% vs 45.3%; p < 0.01). Conclusions: Therefore, mitral valve
reconstruction appears to be the procedure of choice for isolated, nonrheu-
matic disease, whereas insertion of a St. Jude Medical valve should be
preferred for patients with multiple valve disease. (J Thorac Cardiovasc Surg
1998;115:389-96)
Numerous long-term studies have substantiatedthe excellent durability and freedom from struc-
tural degeneration and valve-related complications
provided by mitral valve reconstruction.1-4 Likewise,
the St. Jude Medical valve (St. Jude Medical, Inc.,
St. Paul, Minn.) in the mitral position has repeatedly
been shown to provide excellent durability and
hemodynamic function.5-7 The St. Jude Medical
valve in the mitral position also has been reported to
perform well compared with tissue prostheses8 and
has demonstrated superior freedom from valve-
related complications compared with earlier me-
chanical valves.5 Use of any mechanical valve, how-
ever, exposes the patient to an incremental risk of
thromboembolism and anticoagulant-related com-
plications.
Unfortunately, few direct comparisons have been
made between the performance of the St. Jude
Medical valve in the mitral position and mitral valve
reconstruction among various patient groups.4 Such
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studies might prove particularly informative in view
of the demonstrated inferior durability of mitral
reconstruction in rheumatic patients. We attempted
to address this issue by retrospectively comparing
our institution’s experience with St. Jude Medical
mitral valve replacement and mitral valve recon-
struction with regard to both patient survival and
valve-related complications.
Patients and methods
From January 1976 through July 1996, 2631 patients
underwent mitral valve surgery at New York University
Medical Center. Of the 677 patients who underwent
mechanical valve replacement, 514 (75.9%) received St.
Jude Medical valves (SJMV). Of the 1049 patients who
underwent mitral valve reconstruction, “ringed” mitral
reconstructions (MVP) (Carpentier mitral annuloplasty
rings; Baxter Healthcare, Edwards CVS Division, Irvine,
Calif.) were performed in 725 (69.1%). Replacements
with other mechanical or tissue valves were excluded from
the analysis of mitral replacements; Kay or Reed annulo-
plasties, pure mitral commisurotomies, and mitral annu-
loplasties without ring placement were excluded from the
analysis of mitral reconstructions.
The mean patient age was 60.9 years (range 1 to 83
years) for the SJMV patients and 59.4 years (range 3 to 87
years) for the MVP patients. Concomitant bypass surgery
was performed in 86 (16.7%) of the SJMV patients and
219 (30.2%) of the MVP patients (p , 0.001). Concomi-
tant valvular heart surgery was performed in 243 (47.3%)
of the SJMV patients and 94 (13.0%) of the MVP patients
(p , 0.001). The distribution of the causes of the valvular
disease in the SJMV and MVP patients is listed in Table
I. Fifty-two percent (267/514) of the SJMV mitral replace-
ments were in patients with rheumatic disease, whereas
the preponderance (66.1%, 479/725) of valves treated with
MVP were in patients with degenerative or ischemic
mitral disease. To attempt to identify any relative advan-
tages of use of the SJMV or MVP approaches for specific
types of patients, this study was further restricted to the
following subgroups: patients without rheumatic valve
disease undergoing isolated mitral procedures; patients
with rheumatic disease undergoing isolated mitral proce-
dures; and patients with multiple valve disease undergoing
mitral procedures plus one or more other valve proce-
dures irrespective of the cause of their mitral disease.
Table II gives the basic characteristics of the overall
patient group and these subgroups.
The ultimate choice of valve operation was determined
by technical feasibility and surgeon preference. Operative
techniques included moderate hypothermia and intermit-
tent cold blood cardioplegia. Since 1987, retrograde car-
dioplegia has been used in most operations. The tech-
niques used for the mitral valve reconstructions and
criteria for patient selection have been reported else-
where.9 Throughout most of the study period, the poste-
rior subvalvular apparatus was preserved when the mitral
valve was replaced.
Although this was a nonrandomized study, most of data
for this study were collected prospectively. Patient fol-
low-up was performed at 6-month intervals with a nurse
specialist interviewing the patient. Three hundred forty
patients had a follow-up interval longer than 5 years; 51
patients had a follow-up interval longer than 10 years
(mean follow-up 39.8 months; 98.5% complete; total
follow-up 4045 patient-years). The recommended guide-
lines for nomenclature and reporting morbidity and mor-
tality after cardiac valvular operations were observed.10
Data were analyzed using SPSS statistical software (SPSS,
Inc., Chicago, Ill.). Comparisons of categoric variables
were performed with the x2 test; continuous variables
were compared by the nonpaired Student’s t test. Survival
and freedom from late complications were determined by
life table methods and the Wilcoxon (Gehan) statistic was
used for intergroup comparisons. The Cox proportional
hazards regression model was used to examine multiple
predictors of time-related events.
Results
Table II lists the basic clinical characteristics of all
the patients who received either MVP or mitral
valve replacement with a SJMV and the isolated
nonrheumatic, isolated rheumatic, and multivalve
subgroups. Table III compares the basic clinical
Table I. Etiology of the valvular disease in mitral
valve reconstructions (MVP) and St. Jude Medical
mitral valve replacements (SJMV)
MVP patients
(%)
STMJ patients
(%)
Rheumatic 144 (19.9) 267 (52.0)
Degenerative 356 (49.1) 143 (27.8)
Ischemic 123 (17.0) 12 (2.3)
Infection 60 (8.3) 29 (5.6)
Congenital 34 (4.7) 2 (0.4)
Other 8 (1.1) 61 (11.9)
Total 725 514
Table II. Basic characteristics for all patients, and
isolated, nonrheumatic, isolated, rheumatic, and
multivalve patient subgroups
All
Isolated,
nonrheumatic
Isolated,
rheumatic Multivalve
No. of patients 1239 377 182 337
Mean age
(yr)
60.9 57.6 54.9 60.5
% Male 48.7 (603) 55.7 (210) 23.1 (42) 41.5 (140)
NYHA class
3 or 4 (%)
1008 (81.4) 254 (67.4) 148 (81.3) 304 (90.2)
Pure mitral
insufficiency
(%)
941 (75.9) 344 (91.2) 81 (44.5) 202 (59.9)
Mixed insuf-
ficiency and
stenosis (%)
298 (24.0) 33 (8.8) 101 (55.5) 135 (40.1)
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characteristics of MVP and mitral valve replace-
ment with a SJMV in the isolated, nonrheumatic
and the isolated, rheumatic subgroups. In the iso-
lated, nonrheumatic subgroup, MVP patients had a
greater incidence of degenerative disease (75% vs
58%; p , 0.01), a higher proportion of men (60% vs
42%; p , 0.01), and a better mean preoperative
New York Heart Association classification (2.8 vs
3.3; p , 0.001). In addition, preoperatively 46.2%, of
the SJMV patients had atrial fibrillation/flutter com-
pared with 35.1% of the MVP (p 5 0.06). Postop-
eratively, 99% of the SJMV patients were on a
warfarin sodium (Coumadin) regimen compared
with only 33% of the MVP patients (p , 0.001).
In the isolated, rheumatic subgroup, MVP pa-
tients had a significantly lower mean age (p 5
0.001), more men (32% vs 17%, p 5 0.02), and a
better mean preoperative New York Heart Associ-
ation classification (2.8 vs 3.3; p 5 0.001). Similar to
the isolated, nonrheumatic group, a higher inci-
dence of mixed mitral insufficiency/mitral stenosis
was observed in the SJMV group (70% vs 36%, p 5
0.001).
A comparison of preoperative risk factors for
patients with multivalve procedures is shown in
Table IV. It is important to note that 50% of these
MVP patients had a rheumatic cause for their
valvular heart disease. In 72% of the patients with
multivalve replacements, the second valve operation
was aortic valve replacement. Among the SJMV
patients 100% had a second St. Jude Medical valve
placed, whereas 54% of the MVP had a second valve
placed.
Overall operative mortality was 7.2% for the
SJMV patients and 5.4% for the MVP patients; for
isolated mitral valve operations the mortality was
2.5% and 2.2%, respectively. Table V lists the
actuarial survival of patient subgroups from late
cardiac death, freedom from reoperation for valve
dysfunction, and freedom from all valve-related
complications (thromboembolic, anticoagulant re-
lated, and endocarditis). Table VI lists the actuarial
survival from the individual valve-related complica-
tions. Cox proportional hazards regression revealed
that concomitant coronary artery bypass grafting
significantly decreased the survival from late cardiac
death in all patients (eb 5 1.88; 95% confidence
intervals 1.51 to 2.34; p , 0.001). The linearized
valve-related complication rates for all patients and
for patients with isolated nonrheumatic disease are
listed in Table VII.
In the subgroup of patients with isolated nonrheu-
matic mitral disease, MVP patients experienced
significantly better survival from late cardiac death
than the SJMV patients (95.4% vs 91.6%, respec-
tively, at 8 years; p 5 0.03) and better freedom from
both late cardiac death and reoperation (88.3% vs
86.0%, respectively, at 8 years; p 5 0.05). Multiva-
riable analysis in these patients revealed that per-
formance of an MVP procedure was independently
associated with increased survival from late cardiac
death (expb 5 2.07; 95% confidence interval 1.1 to
3.90; p 5 0.02), irrespective of cause, gender, pre-
operative New York Heart Association classifica-
tion, or cardiac rhythm.
Table III. Comparison of basic characteristics of mitral valve reconstruction (MVP) and St. Jude mitral valve
replacement (SJMV) patients in isolated, nonrheumatic and isolated, rheumatic patient subgroups
Isolated, nonrheumatic Isolated, rheumatic
MVP SJMV p Value MVP SJMV p Value
No. of patients 286 91 76 106
Mean age (yr) 57.2 58.9 0.34 48.8 59.3 0.001
No. male (%) 172 (60.1) 38 (41.8) 0.002 24 (31.6) 18 (17.0) 0.02
Mean NYHA class 2.8 3.3 0.001 2.8 3.3 0.001
Mixed insufficiency and
stenosis (%)
5 (1.8) 28 (30.8) 0.001 27 (35.5) 74 (69.8) 0.001
Degenerative type (%) 214 (74.8) 53 (58.2) 0.002
Ischemic type (%) 10 (3.5) 2 (2.2) 0.74
Table IV. Univariable analysis of preoperative
factors in patients undergoing multivalve mitral
operation
SJMV
patients
MVP
patients
p
Value
No. of patients 243 94
Mean age (yr) 61.1 58.7 .0.05
No. male (%) 88 (36) 52 (55) ,0.01
Mean preoperative NYHA
classification
3.5 3.1 ,0.01
Degenerative etiology (%) 64 (26) 29 (31) ,0.01
Rheumatic etiology (%) 134 (55) 46 (50) .0.05
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A comparison of the patients with isolated rheu-
matic disease in both groups failed to reveal any
significant differences in freedom from late cardiac
death, reoperation, or all valve-related complica-
tions (Table V). The relatively small number of
patients in each group, however, should be noted.
In the multivalve subgroup the SJMV patients
fared better than MVP patients in freedom from
late cardiac death and reoperation (89.4% vs 50.0%
at 8 years; p , 0.001) (Table V). This difference was
also noted in freedom from late cardiac death,
reoperation, and all valve-related complications
(SJMV 77.0% vs MVP 45.3% at 8 years; p , 0.001).
The SJMV patients in this subgroup also had better
freedom from reoperation (SJMV 99.0% vs MVP
76.1% at 8 years; p , 0.01), endocarditis (SJMV
99.5% vs MVP 91.3% at 8 years; p 5 0.03), and
thromboembolic complications (SJMV 91.7% vs
MVP 84.7% at 8 years; p 5 0.02) (Table VI).
Discussion
The results presented here show that both St.
Jude Medical mitral valve replacement and mitral
valve reconstruction provided good results in the
overall patient group with freedom from late cardiac
death, reoperation, and all valve-related complica-
tions at 8 years of 72.8% for SJMV replacement and
64.8% for MVP (p . 0.13) (Table V). As noted
previously, however, concomitant coronary artery
bypass grafting profoundly diminished survival from
late cardiac death in all patients. When various
other subgroups are compared, additional impor-
tant distinctions emerge.
Isolated, nonrheumatic mitral insufficiency. For
isolated mitral insufficiency in patients with non-
rheumatic disease, mitral reconstruction appears to
provide some advantages, with an 8-year survival
from late cardiac death of 95.4% compared with
91.6% for the SJMV group (p 5 0.03). Likewise in
this subgroup, 8-year freedom from late cardiac
death and reoperation was marginally significantly
better in the MVP group (88.3%) compared with
the SJMV group (86.0%; p 5 0.05). It might be
suggested that this difference in survival from late
cardiac death was due to significant differences in
the incidence and severity of preoperative risk fac-
tors between the SJMV and MVP groups, as shown
in Table III. However, multivariable analysis
showed that only the use of MVP was a significant
predictor of survival from late cardiac death. This
may be related to the fact that although both groups
had comparable freedom from major late valve-
related complications (Table VI), the complications
in the SJMV group were more likely to be fatal,
resulting in this group’s lower survival from late
cardiac death (Table V).
Table V. Freedom from late cardiac death (LCD), valve related mortality (VRM), reoperation (REOP), and all
valve-related complications (AVC) in various groups of patients undergoing mitral St. Jude Medical valve
replacement (SJMV) or mitral reconstruction (MVP). The percentage is listed with the number of patients
entering the follow-up interval in parentheses. P values are for entire 8-year time span
Freedom from
5 Years 8 Years
p ValueSJMV MVP SJMV MVP
All patients
LCD 90.2 (130) 90.9 (268) 89.3 (31) 84.1 (129) 0.90
LCD and REOP 86.6 (130) 82.9 (268) 83.4 (31) 73.1 (129) 0.09
LCD, REOP and AVC 80.4 (121) 74.4 (255) 72.8 (25) 64.8 (117) 0.13
Isolated, nonrheumatic etiology
LCD 91.6 (25) 98.1 (108) 91.6 (7) 95.4 (59) 0.03
VRM 97.6 (25) 100 (108) 97.6 (7) 100 (59) 0.07
LCD and REOP 86.0 (25) 93.6 (108) 86.0 (7) 88.3 (59) 0.05
LCD, REOP, and AVC 82.5 (23) 87.5 (106) 82.5 (6) 82.1 (58) 0.42
Isolated, rheumatic etiology
LCD 97.0 (30) 98.1 (37) 97.0 (9) 98.1 (14) 0.70
LCD and REOP 89.5 (30) 84.0 (37) 89.5 (9) 84.0 (14) 0.33
LCD, REOP, and AVC 82.5 (28) 71.5 (34) 74.7 (6) 71.5 (12) 0.26
Multivalve procedure
LCD 90.3 (60) 81.1 (47) 90.3 (14) 64.4 (24) 0.17
VRM 99.5 (60) 95.4 (47) 99.5 (14) 95.4 (24) 0.12
LCD and REOP 89.4 (60) 71.8 (47) 89.4 (14) 50.0 (24) ,0.001
LCD, REOP, and AVC 83.4 (57) 64.3 (44) 77.0 (12) 45.3 (21) ,0.001
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Isolated rheumatic mitral insufficiency. Prior re-
ports have documented that patients with isolated
rheumatic mitral disease do not obtain as much
long-term benefit from mitral repair as do patients
with nonrheumatic disease.1, 2 We have previously
reported freedom from reoperation at 5 years for a
group of all patients with rheumatic disease under-
going mitral reconstruction to be only 77.4%.2 In
recent years refinements in our selection criteria for
patients undergoing mitral reconstruction, as well as
improvements and innovations in mitral reconstruc-
tion, have improved freedom from reoperation for
isolated mitral reconstruction with a ring in patients
with rheumatic disease to 85.6% at 8 years. Never-
theless, the fact that the SJMV-isolated rheumatic
replacement group does not show a significantly
better freedom from reoperation compared with a
similar group of MVP patients may be because so
few patients were in the follow-up at 8 years. In the
future, a longer follow-up period with a greater
number of patients should reveal a difference in
freedom from reoperation between SJMV and
MVP patients because of the known progression of
the rheumatic valvular disease.
Nevertheless, the possibility of using mitral valve
reconstruction in patients with isolated rheumatic
mitral valve disease should not be summarily ex-
cluded. Under certain circumstances, such as in a
woman of child-bearing age and intention, the ad-
vantages of mitral reconstruction with the reduced
need for an anticoagulant regimen could well out-
weigh considerations based on the inferior durabil-
Table VI. Freedom from reoperation for valve dysfunction (REOP), endocarditis (ENDO), thromboembolic
complications (TE), and anticoagulant-related complications (ANTIC) in various groups of patients undergoing
mitral St. Jude Medical valve replacement (SJMV) or mitral reconstruction (MVP). Listed is cumulative
percentage complication free and in parenthesis the number of patients entering the follow-up interval; p values
are for entire 8-year time span
Freedom from
5 Years 8 Years
p ValueSJMV MVP SJMV MVP
All patients
REOP 95.5 (130) 90.8 (268) 93.4 (31) 86.5 (129) 0.01
ENDO 99.0 (129) 97.1 (268) 99.0 (31) 95.7 (128) 0.22
TE 94.7 (124) 91.7 (258) 89.5 (26) 90.6 (121) 0.40
ANTIC 96.2 (128) 97.6 (262) 95.1 (30) 97.6 (124) 0.40
Isolated nonrheumatic etiology
REOP 91.6 (25) 95.4 (108) 91.6 (7) 92.6 (59) 0.30
ENDO 100 (25) 96.3 (108) 100 (7) 94.5 (59) 0.20
TE 96.3 (23) 97.3 (107) 96.2 (6) 97.3 (59) 0.83
ANTIC 97.6 (25) 98.7 (106) 97.6 (7) 98.7 (58) 0.78
Isolated rheumatic etiology
REOP 92.3 (30) 85.6 (37) 92.3 (9) 85.6 (12) 0.21
ENDO 97.8 (30) 100 (37) 97.8 (9) 100 (14) 0.24
TE 94.6 (28) 85.7 (34) 85.6 (6) 85.7 (12) 0.36
ANTIC 97.8 (30) 97.5 (36) 97.8 (9) 97.5 (13) 0.44
Multivalve procedure
REOP 99.0 (60) 86.7 (47) 99.0 (14) 76.1 (24) ,0.01
ENDO 99.5 (60) 94.0 (47) 99.5 (14) 91.3 (23) 0.03
TE 96.4 (59) 87.3 (45) 91.7 (13) 84.7 (23) 0.02
ANTIC 95.7 (58) 96.2 (46) 93.3 (13) 96.2 (23) 0.87
Table VII. Linearized complication rates (percent
per patient-year) for reoperation for valve
dysfunction (REOP), endocarditis (ENDO),
thromboembolic complications (TE), and
anticoagulant related complications (ANTIC) in all
patients undergoing mitral St. Jude Medical valve
replacement (SJMV) or mitral reconstruction (MVP)
Complication
All patients
Isolated
nonrheumatic
SJMV MVP SJMV MVP
REOP 1.08 2.22 1.92 1.00
ENDO 0.29 0.58 0.00 0.64
TE 1.40 1.59 0.79 0.74
ANTIC 0.95 0.51 0.38 0.37
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ity of mitral reconstruction in patients with rheu-
matic mitral valve disease.
Patients with multivalve disease. All the SJMV
patients who underwent concomitant aortic valve
replacement had another St. Jude Medical valve
placed in the aortic position, whereas among the
MVP patients only half the concomitant aortic valve
replacements were done with a St. Jude Medical
valve. In patients with multivalve disease the differ-
ences between the SJMV and MVP groups for late
cardiac death or valve-related mortality were not
statistically significant (Table V). However, the re-
sults for the SJMV group were significantly better
for freedom from late cardiac death and reoperation
and for freedom from late cardiac death, reopera-
tion, and all valve-related complications. As might
be anticipated in patients with double valve disease,
50% of the MVP patients and 55% of the SJMV
patients had rheumatic mitral disease. The high
number of reoperations and valve-related complica-
tions in the MVP group may be attributable to the
known inferior durability of MVP in patients with
rheumatic disease.
The major weakness of this study is that the
patients were not randomized into the MVP and
SJMV study groups. However, we have attempted to
describe any factors that may have affected treat-
ment selection and results.
In conclusion, the present results suggest that in
patients with isolated nonrheumatic mitral valve
disease, repair offers better freedom from late
cardiac death and reoperation. In patients with
isolated rheumatic mitral valve disease, mitral
valve reconstruction, although its durability is not
as good as in patients without rheumatic disease,
offers a great advantage in certain subgroups of
patients in whom the need to avoid anticoagula-
tion exists. In patients with multiple valve disease,
St. Jude Medical valve replacement offered better
freedom from combined late cardiac death, reop-
eration, and all valve-related complications.
Therefore mitral valve repair appears to be the
procedure of choice for patients with isolated,
nonrheumatic valve disease, whereas St. Jude
Medical mitral valve replacement seems to pro-
vide improved late results in patients with multi-
ple valve disease.
R E F E R E N C E S
1. Galloway AC, Colvin SB, Baumann FG, Esposito R, Vohra
R, Harty S, et al. Long-term results of mitral valve recon-
struction with Carpentier techniques in 148 patients with
mitral insufficiency. Circulation 1988;78(Suppl):I-97-105.
2. Ga11oway AC, Colvin SB, Baumann FG, Grossi EA, Riba-
kove GH, Harty S, et al. A comparison of mitral valve
reconstruction with mitral valve replacement: intermediate
term results. Ann Thorac Surg 1989;47:655-62.
3. Deloche A, Jebara VA, Relland JY, Chauvaud S, Fabiani JN,
Perier P, et al. Valve repair with Carpentier techniques: the
second decade. J Thorac Cardiovasc Surg 1990:99:990-1002.
4. Akins CW, Hilgenberg AD, Buckley MJ, Vlahakes GJ,
Torchiana DF, Daggett WM, et al. Mitral valve reconstruc-
tion versus replacement for degenerative or ischemic mitral
regurgitation. Ann Thorac Surg 1994;58:668-76.
5. Akins CW. Mechanical cardiac valvular prostheses. Ann
Thorac Surg 1991;52:161-72.
6. Jegaden O, Eker A, Delahaye F, Montagna P, Ossette J, de
Gevigney GD, et al. Thromboembolic risk and late survival
after mitral valve replacement with the St. Jude Medical
valve. Ann Thorac Surg 1994;58:1721-8.
7. Fire AC, Naunheim KS, D’Orazio S, Kaiser GC, McBride
LR, Pennington G, et al. Mitral valve replacement: random-
ized trial of St. Jude and Medtronic-Hall prostheses. Ann
Thorac Surg 1992;54:68-73.
8. Hammermeister KE, Gulshan K, Sethi GK, Henderson WG,
Oprian C, Kim T, et al. A comparison of outcomes in men 11
years after heart valve replacement with mechanical valve or
bioprostheses. N Engl J Med 1993;328:1289-96.
9. Galloway AC, Colvin SB, Baumann FG, et al: Current
concepts of mitral valve reconstruction for mitral insuffi-
ciency. Circulation 1988;78:1087-98.
10. Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller
DC, Weisel RD. Guidelines for reporting morbidity and
mortality after cardiac valvular operations. J Thorac Cardio-
vasc Surg 1996;112:708-11.
Discussion
Dr. Cary W. Akins (Boston, Mass.). Previous compari-
sons of mitral valve replacement and mitral valve recon-
struction, including our own, have almost invariably dem-
onstrated an advantage in event-free survival for mitral
valve reconstruction versus mitral valve replacement, es-
pecially when the operations are done for degenerative or
ischemic mitral regurgitation. Today in a large, long-term
study comparing mitral valve reconstruction and mitral
valve replacement with a St. Jude Medical mechanical
prosthesis, Grossi and colleagues have examined the
freedom from late cardiac death and valve-related com-
plications after the two operations in all patients.
As expected, mitral valve reconstruction patients in the
nonrheumatic subgroup had significantly better freedom
from late cardiac death and late cardiac death or reop-
eration than the St. Jude Medical mitral valve replace-
ment patients. In addition, by multivariate analysis, only
mitral valve reconstruction predicted improved freedom
from late cardiac death.
The study then compares patients with rheumatic mitral
valve disease and patients having multivalve operations. In
the abstract for the rheumatic subgroup, patients with the
St. Jude Medical mitral valve replacement had better
freedom from late cardiac death and reoperation, but in
the manuscript no significant difference was observed. In
the multivalve subgroup, both in the abstract and the
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manuscript, St. Jude Medical mitral valve replacement
was associated with better freedom from late cardiac
death, reoperation, and valve-related complications. The
authors suggest that some of this can be explained by the
well-known higher reoperation rate after mitral valve
reconstruction in patients with rheumatic mitral valve
disease. Are there other possible explanations?
Concomitant coronary artery bypass grafting was per-
formed twice as often in the mitral valve reconstruction
patients as in the St. Jude Medical valve replacement
patients, and the authors statistically document the impor-
tant negative influence of coronary artery disease on late
survival.
My first question to the authors is, did you assess the
impact of concomitant coronary disease on survival for the
two operations in the patients with rheumatic and multi-
valve disease? Indeed, while you performed a multivariate
analysis of the risk factors for patients with nonrheumatic
disease, you did not for those with rheumatic and multi-
valve disease. In a comparison of two disparate and
nonrandomized patient populations, isn’t multivariate
analysis into which procedure performed is inserted as a
variable the best way to assess a multivariate situation?
Secondly, all mitral valve reconstructions were presum-
ably done for isolated mitral regurgitation. My second
question to the authors is whether the St. Jude Medical
valve replacement patients had isolated mitral regurgita-
tion. Is it possible that the inclusion of patients with other
valve diseases in the St. Jude Medical operative group of
rheumatic and multivalve patients influenced the late
results (another question that can be addressed by multi-
variate analysis)?
Finally, in the manuscript the authors list very low
linearized rates for thromboembolism and anticoagulant-
related bleeding for the St. Jude Medical valve replace-
ment patients. In fact, the linearized rates for anticoagu-
lant-related bleeding were all less than 1% per patient-
year. Yet we know from the placebo arms of the various
randomized trials of anticoagulants that the background
rate of bleeding in the normal population varies from 1%
and 1.5% per patient-year. How did the authors define
anticoagulant-related bleeding, and how do they account
for bleeding rates in an anticoagulated population that are
lower than the background rate of bleeding in the unan-
ticoagulated population?
Dr. Jacques R. Seguin (Creteil-Paris, France). I would
like to congratulate the authors on this excellent presen-
tation and to thank the New York University team for
promoting valve repair with such wonderful results.
I think, like your team, in nonrheumatic disease, mitral
regurgitation can be repaired in a very large group of
patients, probably more than 90% of the patients, whereas
I do not share totally your conclusions concerning patients
with rheumatic disease. We have the impression there is
not one type of rheumatic disease but multiple types of
thoracic lesions, and to make things simple, probably two
groups of patients: one with severely calcified anterior
leaflet where repair might not be advisable, whereas in
patients with calcified posterior leaflets, repair is possible
with excellent long-term results. Don’t you think there are
different types of patients with rheumatic lesions and they
should be differentiated in your presentation and thus
possibly modify your conclusions?
Dr. Manuel J. Antunes (Coimbra, Portugal). I concur
with your conclusions inasmuch as the results for repair
for rheumatic mitral valve disease are usually worse than
those for nonrheumatic valves, although in your conclu-
sions it appears that the difference was only for patients
with multivalve disease. However, your rheumatic popu-
lation is a selected one; I am quite sure about that. Hence,
in my view, you could be sending out the wrong message.
Most of the patients with rheumatic valve disease
operated on now are from a Third World population. I
continue to operate on many patients coming from Africa,
and the last one that I operated on, only about a couple of
weeks ago, was 4 years old. In this patient, replacing a
valve with a mechanical or with a tissue valve would be
short of a crime, I think. And our results have shown that
in that particular population, the results of mitral valve
repair are still better than those of mitral valve replace-
ment. Hence, I urge surgeons treating these types of
patients to continue concentrating their efforts in repair-
ing valves.
Currently in Portugal, where two thirds of our patients
still have rheumatic disease, we repair approximately 85%
of all mitral valves coming to operation and continue to be
pleased with the results. New techniques have been added
to surgeons’ armamentarium since 1980 when you started
your series, and today your story may be a little bit
different from that which you depicted. Do you have any
information about these questions? Are your results today
better than they were in 1980 in respect to rheumatic
valves?
Dr. Alain F. Carpentier (Paris, France). Any conclusion
coming from this group is very important to take into
consideration, particularly when we do not think exactly
the same way.
I do have two questions. Number one, you mentioned
that you had 51 patients over 10 years, 51 patients overall,
and based on your presentation, apparently you have
about one fourth of your total cohort being rheumatic and
three fourths being degenerative.
Now, going back to the 8-year prediction or your 8-year
conclusion, if you have only 51 patients beyond 10 years,
one fourth means only, let’s say, 15% of rheumatic valve
disease. How can you derive such a conclusion from 15
patients over 10 years? This is my first question.
Now number two, as far as multiple valve disease is
concerned, when you are comparing multiple-valve re-
placement with multiple-valve repair, does this imply that
these patients had aortic valve repair because we all know
that aortic valve repair does not work and should not be
used. So if you compare a technique that works in the
mitral position with a technique that does not work in the
aortic position, probably your conclusion is not valid.
Dr. Grossi. Dealing with the questions, first to clarify, in
the isolated rheumatic group that we presented, there was
no concomitant bypass surgery. The isolated rheumatic
patients were those patients with rheumatic etiology un-
dergoing isolated mitral valve replacement or repair with-
out concomitant bypass surgery. So we do not think that
was a problem. It was impossible to add that as an
additional risk factor.
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We demonstrated in the manuscript that overall, look-
ing at all the patients, multivariate analysis showed that
the effect of concomitant bypass grafting has the greatest
single effect on long-term freedom from late cardiac
death.
With regard to the cause of the valve diseases, all these
patients had mitral insufficiency. Of those patients who
had rheumatic causes, approximately 15% of them had
some element of mitral stenosis in addition to that, and
that was equal across both the replacements and the
reconstructions.
With regard to the linearized rates of anticoagulated
bleeding, I do not think in terms of linearized rates. I was
quite happy when our rates were calculated. We looked at
them, and we thought they were within the table of the
review article Dr. Akins had published; they were well
within the standard errors of those. The complications
that we count as anticoagulants causing bleeding are
defined according to the guidelines published in The
Journal of Thoracic and Cardiovascular Surgery.
With regard to the different types of rheumatic disease
in terms of anterior calcification versus posterior calcifi-
cation, we did not quantify that or put a label on that type
of rheumatic disease and break down our patients into
those groups. These are patients with rheumatic disease
who we see in North America, and we do have a large
percentage of them.
With regard to Professor Carpentier’s questions, we do
have patients out 15 years after reconstruction, and our
reconstruction data goes out that far. We could not
present that here because it would be meaningless; we do
not have enough data for a uniform mechanical group.
With regard to the patients with multiple valve disease,
it is sort of an interesting group. Of those, most of them
were aortic valve replacements and either mitral valve
replacements or reconstructions. Of those, 50% had ei-
ther a mechanical valve placed in their aortic valve or a
tissue valve placed in their aortic valve. So these are not
aortic valve reconstructions.
Specifically when we are talking about the freedom
from reoperation, this is with regard to dysfunction of the
mitral valve.
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